Stockreport

Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

Myriad Genetics, Inc.  (MYGN) 
Last myriad genetics, inc. earnings: 2/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: myriad.com/news-center/investor-information
PDF SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing, commends the updated Prostate Ca [Read more]